Lb Pharmaceuticals (LBRX) Net Cash Flow (2024 - 2026)

Lb Pharmaceuticals' Net Cash Flow history runs 3 years deep, the most recent figure standing at $70.5 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 2339.49% year-over-year to $70.5 million in Q1 2026; TTM through Mar 2026 was $48.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $227.5 million, up 2577.12% from the prior year.
• Net Cash Flow rose to $70.5 million in Q1 2026 per LBRX's latest filing, from -$19.3 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $70.5 million in Q1 2026 and bottomed at -$19.3 million in Q4 2025.
• The 3-year median for Net Cash Flow is $2.4 million (2024), against an average of $14.0 million.
• Across the five-year window, Net Cash Flow slumped 345.27% in 2025 and soared 2339.49% in 2026, its largest moves.
• Year by year, Net Cash Flow stood at $7.9 million in 2024, then sank by 345.27% to -$19.3 million in 2025, then surged by 465.09% to $70.5 million in 2026.
• Per Business Quant, the three latest LBRX Net Cash Flow figures stand at $70.5 million (Q1 2026), -$19.3 million (Q4 2025), and -$3.1 million (Q1 2025).